[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-458854-en":59,"doc-seo-458854-105":80},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":72,"language_code":73,"site_id":74,"html_lang":73,"table_of_contents":75,"faqs":76,"seo_title":77,"seo_description":66,"update_tm":78,"read_time":79,"preview_page_count":4},458854,962090769181,"Rainbow Cat","https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020","Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016–2020 evaluates how different anti-tuberculosis regimens affect pregnancy safety among women who became pregnant during the study. Among 740 women, 97 became pregnant and 102 pregnancies included exposure in 30 participants. Fetal loss rates were compared across control and rifapentine/moxifloxacin or rifapentine arms, and congenital anomaly occurrence was assessed among exposed live births. Findings indicate no elevated rates of fetal loss or congenital anomalies with a short rifapentine/moxifloxacin regimen during pregnancy.","RESEARCH  \nPregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial,  \n2016–2020  \nEkaterina V. Kurbatova, William C. Whitworth, Kia E. Bryant, Meredith G. Dixon, Kelly E. Dooley, Nigel A. Scott, Rosanna Boyd, Nicole E. Brown, Kimberley N. Chapman Hedges, Wendy Carr, Lakshmi P. Peddareddy, Grace Muzanyi, Rodney Dawson, Ziyad Waja, Neil Martinson, Jyoti S.V. Mathad, Payam Nahid, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, Patrick P.J. Phillips, AIDS Clinical Trials Group A5349,1 Tuberculosis Trials Consortium Study 312  \nIn support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  \nMedscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.  \nSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  \nAll other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity:  \n(1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at [http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions,](http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions,)[ ](http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions,)[see page 2357.](see page 2357.)  \nNOTE: It is the policy of Medscape Education to avoid the mention of brand names or specific manufacturers in accredited educational activities. However, trade and manufacturer names in this activity are provided in an effort to provide clarity. The use of brand or manufacturer names should not be viewed as an endorsement by Medscape of any specific product or manufacturer.  \nRelease date: December 29, 2025; Expiration date: December 29, 2026  \nLearning Objectives  \nUpon completion of this activity, participants will be able to:  \n• Compare the efficacy of 4-vs 6-month anti-tuberculosis (TB) regimens among women  \n• Evaluate the rate of fetal loss among women exposed to anti-TB treatment during pregnancy  \n• Evaluate the rate of congenital anomaly among women exposed to anti-TB treatment during pregnancy  \n• Analyze the effects of anti-TB treatment during pregnancy on favorable TB outcomes  \nCME Editor  \nJude Rutledge, BA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jude Rutledge, BA, has no relevant financial relationships.  \nCME Author  \nCharles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: consultant or advisor for Boehringer Ingelheim; Exact Sciences.  \nAuthors  \nEkaterina V. Kurbatova, MD, MPH, PhD; William C. Whitworth, MPH; Kia E. Bryant, MPH; Meredith G. Dixon, MD, FAAP; Kelly E. Dooley, MD, PhD; Nigel A. Scott, MS; Rosanna Boyd, PhD; Nicole E. Brown, PhD; Kimberley N. Chapman Hedges, MPH; Wendy Carr, PhD; Lakshmi P. Pedd","cbCaihgm8rUdehHy","https://ap.wps.com/l/cbCaihgm8rUdehHy","pdf",765533,"English","en",105,"# Learning Objectives\n## Compare efficacy of 4- vs 6-month anti-TB regimens\n## Evaluate fetal loss during pregnancy\n## Evaluate congenital anomalies during pregnancy\n## Analyze effects on favorable TB outcomes","[{\"question\":\"How many women became pregnant during the trial, and how many pregnancies involved drug exposure?\",\"answer\":\"Among 740 women, 97 (13.1%) became pregnant, with 102 pregnancies in those participants. Thirty pregnancies (in 30 participants) reported exposure to the study drugs.\"},{\"question\":\"What were the reported fetal loss rates across the study arms?\",\"answer\":\"Fetal loss was reported for 3/13 (23.1%) in the control regimen, 1/9 (11.1%) in the rifapentine/moxifloxacin regimen, and 1/8 (12.5%) in the rifapentine regimen.\"},{\"question\":\"Did exposure to short rifapentine/moxifloxacin during pregnancy increase fetal loss or congenital anomalies?\",\"answer\":\"No elevated rates of fetal losses or congenital anomalies were observed among women receiving the short rifapentine/moxifloxacin regimen who became pregnant.\"}]","Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020 | PDF",1790754618,25,{"code":4,"msg":81,"data":82},"ok",{"site_id":74,"language":73,"slug":83,"title":65,"keywords":84,"description":66,"schema_data":85,"social_meta":139,"head_meta":141,"extra_data":143,"updated_unix":144},"pregnancy-outcomes-after-exposure-to-tuberculosis-treatment-in-phase-3-clinical-trial-2016-2020","",{"@graph":86,"@context":138},[87,101,121],{"@type":88,"itemListElement":89},"BreadcrumbList",[90,94,96,99],{"item":91,"name":92,"@type":93,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":95,"name":9,"@type":93,"position":14},"https://docshare.wps.com/document/",{"item":97,"name":35,"@type":93,"position":98},"https://docshare.wps.com/document/healthcare/",3,{"item":100,"name":65,"@type":93,"position":19},"https://docshare.wps.com/document/pregnancy-outcomes-after-exposure-to-tuberculosis-treatment-in-phase-3-clinical-trial-2016-2020/458854/",{"url":100,"name":65,"@type":102,"image":103,"author":108,"headline":65,"publisher":110,"fileFormat":113,"inLanguage":73,"description":66,"dateModified":114,"datePublished":115,"encodingFormat":113,"isAccessibleForFree":116,"interactionStatistic":117},"DigitalDocument",{"url":104,"@type":105,"width":106,"height":107},"https://docshare.wps.com/thumbnails/pregnancy-outcomes-after-exposure-to-tuberculosis-treatment-in-phase-3-clinical-trial-2016-2020/458854.png","ImageObject",300,407,{"name":63,"@type":109},"Person",{"url":91,"name":111,"@type":112},"DocShare","Organization","application/pdf","2026-11-02","2026-09-30",true,{"@type":118,"interactionType":119,"userInteractionCount":39},"InteractionCounter",{"@type":120},"ViewAction",{"@type":122,"mainEntity":123},"FAQPage",[124,130,134],{"name":125,"@type":126,"acceptedAnswer":127},"How many women became pregnant during the trial, and how many pregnancies involved drug exposure?","Question",{"text":128,"@type":129},"Among 740 women, 97 (13.1%) became pregnant, with 102 pregnancies in those participants. Thirty pregnancies (in 30 participants) reported exposure to the study drugs.","Answer",{"name":131,"@type":126,"acceptedAnswer":132},"What were the reported fetal loss rates across the study arms?",{"text":133,"@type":129},"Fetal loss was reported for 3/13 (23.1%) in the control regimen, 1/9 (11.1%) in the rifapentine/moxifloxacin regimen, and 1/8 (12.5%) in the rifapentine regimen.",{"name":135,"@type":126,"acceptedAnswer":136},"Did exposure to short rifapentine/moxifloxacin during pregnancy increase fetal loss or congenital anomalies?",{"text":137,"@type":129},"No elevated rates of fetal losses or congenital anomalies were observed among women receiving the short rifapentine/moxifloxacin regimen who became pregnant.","https://schema.org",{"og:url":100,"og:type":140,"og:title":65,"og:site_name":111,"og:description":66},"article",{"robots":142,"canonical":100},"index,follow",{"doc_id":61,"site_id":74},1791165420]